CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Medicine, Inc. (NASDAQ:FMI) today announced the appointment of Tom
Civik to the role of chief commercial officer. Mr. Civik brings to
Foundation Medicine more than two decades of commercial and operational
experience with global biopharmaceutical organizations, most recently
having served as a vice president and officer for Genentech, as well as
previously serving in increasingly complex commercial positions at
Sanofi~Synthelabo. In his new role at Foundation Medicine, Mr. Civik
will be responsible for establishing commercial and reimbursement
strategies to support adoption of Foundation Medicine's expanding suite
of clinical molecular information solutions. Mr. Civik, who is expected
to commence employment with Foundation Medicine in mid-November, will
report to Troy Cox, Foundation Medicine's chief executive officer.
"Tom's proven commercial leadership in shaping oncology portfolio
strategies, launching and growing multiple key oncology products, and
his understanding of the oncology reimbursement landscape will be
critically important as Foundation Medicine approaches key milestones,
including the potential launch of an FDA approved diagnostic assay
following the completion of the parallel review process with FDA and
CMS," stated Troy Cox, chief executive officer for Foundation Medicine.
"We're delighted to welcome Tom to the team, and we look forward to Tom
making substantial contributions as we advance patient access to
personalized healthcare in oncology."
As an accomplished commercial leader, Mr. Civik brings to Foundation
Medicine a proven track record of delivering strong commercial results,
launching blockbuster and targeted therapies, and leading large teams.
Mr. Civik built a distinguished career spanning 17 years in Genentech's
commercial organization. Most recently, Mr. Civik was a vice president
and franchise leader at Genentech, responsible for the commercialization
efforts for several leading oncology products delivering more than $3
billion in revenue. Prior to joining the oncology team at Genentech, Mr.
Civik led the commercial activities for a portfolio of products focused
on stroke and cardiovascular disease. Mr. Civik began his tenure at
Genentech in the managed care area, holding senior leadership roles
focused on delivering access for the entire Genentech portfolio. Prior
to Genentech, Mr. Civik spent eight years at Sanofi where he held
increasingly complex roles in sales, sales management and account
Mr. Civik received a Bachelor of Arts degree from the Saint Norbert
College and a Master's degree in business administration from the
Kellogg School of Management at Northwestern University.
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI)
is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding of
the genomic changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling assays to
identify the molecular alterations in a patient's cancer and match them
with relevant targeted therapies, immunotherapies and clinical trials.
Foundation Medicine's molecular information platform aims to improve
day-to-day care for patients by serving the needs of clinicians,
academic researchers and drug developers to help advance the science of
molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine is a registered
trademark of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements for Foundation
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements regarding
Mr. Civik's joining Foundation Medicine as an employee, Mr. Civik's
ability to play a critical role in helping Foundation Medicine achieve
key milestones, and Mr. Civik's ability to make substantial
contributions to Foundation Medicine. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include Mr. Civik's failure to commence employment at
Foundation Medicine due to personal or professional reasons, Mr. Civik's
responsibilities not being well positioned to materially affect
Foundation Medicine's achievement of critical milestones, Mr. Civic not
having the skills or access to make substantial contributions to
Foundation Medicine, and the risks described under the caption "Risk
Factors" in Foundation Medicine's Annual Report on Form 10-K for the
year ended December 31, 2016, which is on file with the Securities and
Exchange Commission, as well as other risks detailed in Foundation
Medicine's subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of
the release, and Foundation Medicine undertakes no duty to update this
information unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171010006611/en/
Foundation Medicine, Inc.
Kimberly Brown, 617-418-2215
Source: Foundation Medicine, Inc.
News Provided by Acquire Media